Compounds > ly 353381
Page last updated: 2024-09-05

ly 353381 and lg 100268

ly 353381 has been researched along with lg 100268 in 4 studies

Compound Research Comparison

Studies
(ly 353381)		Trials
(ly 353381)		Recent Studies (post-2010)
(ly 353381)		Studies
(lg 100268)		Trials
(lg 100268)		Recent Studies (post-2010) (lg 100268)
701215108028

Protein Interaction Comparison

ProteinTaxonomyly 353381 (IC50)lg 100268 (IC50)
Retinoic acid receptor RXR-alphaHomo sapiens (human)0.008

Research

Studies (4)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's4 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Farris, MR; Glasebrook, AL; Grese, TA; Heyman, RA; Lamph, WW; Palkowitz, AD; Risingsong, R; Sporn, MB; Suh, N; Williams, CR1
Berchuck, A; Heyman, RA; Krajewski, S; Lamph, WW; Liby, K; Reed, JC; Rendi, MH; Risingsong, R; Royce, DB; Sporn, MB; Suh, N; Williams, CR1
Hede, K1
Brown, P; Kim, H; Krajewski, S; Labrie, F; Lamph, W; Liby, K; Rendi, M; Risingsong, R; Royce, DB; Sporn, MB; Suh, N; Williams, CR; Xu, X1

Other Studies

4 other study(ies) available for ly 353381 and lg 100268

ArticleYear
Prevention and treatment of experimental breast cancer with the combination of a new selective estrogen receptor modulator, arzoxifene, and a new rexinoid, LG 100268.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:10

    Topics: Animals; Anticarcinogenic Agents; Cells, Cultured; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mammary Neoplasms, Experimental; Methylnitrosourea; Neoplasm Invasiveness; Nicotinic Acids; Nitric Oxide Synthase; Nitric Oxide Synthase Type II; Piperidines; Rats; Selective Estrogen Receptor Modulators; Stromal Cells; Tetrahydronaphthalenes; Thiophenes; Transforming Growth Factor beta

2002
The selective estrogen receptor modulator arzoxifene and the rexinoid LG100268 cooperate to promote transforming growth factor beta-dependent apoptosis in breast cancer.
    Cancer research, 2004, May-15, Volume: 64, Issue:10

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Drug Synergism; Mammary Neoplasms, Experimental; NF-kappa B; Nicotinic Acids; Phosphoinositide-3 Kinase Inhibitors; Piperidines; Rats; Rats, Sprague-Dawley; Selective Estrogen Receptor Modulators; Tetrahydronaphthalenes; Thiophenes; Transfection; Transforming Growth Factor beta

2004
Rexinoids may be ready for prime time in prevention, but challenges remain.
    Journal of the National Cancer Institute, 2004, Dec-15, Volume: 96, Issue:24

    Topics: Animals; Anticarcinogenic Agents; Bexarotene; Breast Neoplasms; Clinical Trials as Topic; Disease Models, Animal; Female; Humans; Nicotinic Acids; Piperidines; Retinoid X Receptors; Tetrahydronaphthalenes; Thiophenes

2004
The combination of the rexinoid, LG100268, and a selective estrogen receptor modulator, either arzoxifene or acolbifene, synergizes in the prevention and treatment of mammary tumors in an estrogen receptor-negative model of breast cancer.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Oct-01, Volume: 12, Issue:19

    Topics: Animals; Cell Division; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Female; Humans; Mammary Neoplasms, Experimental; Mice; Mice, Transgenic; Nicotinic Acids; Piperidines; Receptors, Estrogen; Selective Estrogen Receptor Modulators; Survival Rate; Tetrahydronaphthalenes; Thiophenes

2006